drugset
drugset / Trial / NCT04155411

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

NCT04155411 ↗

Phase 4 Unknown 65 enrolled Shenzhen Second People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML).

Timeline

Start
2019-12-01
Primary completion
2022-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule 70 mg Oral

Indications

chronic myeloid leukemia